The July issue of Dermatology Times highlights some newly approved treatments in dermatology including a new wrinkle filler and new treatment for seborrheic keratosis.
The Food and Drug Administration (FDA) has approved rare pediatric disease designation for diacerein 1 percent ointment (CPP-020, Castle Creek Pharmaceuticals) for the treatment of epidermolysis bullosa (EB).
The subcutaneous formulation of Actemra (tocilizumab, Genentech) has been approved by the Food and Drug Administration (FDA) for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in patients ages 2 years and older, accor
Belgian pharmaceutical firm UCB has entered the immunodermatology field in the U.S. market.
Is it misuse to use medication for off-label uses? A patient sues after developing facial pain and other symptoms associated with the use of a topical for scabies. Is this physician guilty of practicing medicine outside the standard of care?